Novartis Hopes To Breathe New Life Into CAR-T Business With ASCO Myeloma Data

Gilead’s Kite has taken a lead in multiple myeloma cell therapy while Novartis’s first-to-market Kymriah has slumped in sales, but the Swiss drug maker’s new data may support its effort to win on manufacturing time.